Literature DB >> 9544446

Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids.

A R Koudinov1, T T Berezov, A Kumar, N V Koudinova.   

Abstract

We report studies of the interaction of Alzheimer's amyloid beta protein (A beta) with normal human plasma high density lipoprotein (HDL), aiming to clarify to which lipoprotein (LP) structural constituent (apolipoprotein or lipid) soluble A beta is primarily bound. Purified HDLs were incubated with biotinylated A beta 1-40 followed by LP repurification by size exclusion (SE) HPLC. SDS-PAGE, immunoblot and N-terminal sequence analysis of the biotin-A beta positive protein bands revealed that A beta is bound to many apolipoproteins of the HDL, mainly apoA-I, apoA-II, apoE and apoJ. On the other hand, reconstituted, protein-free HDL lipid particles also bind A beta peptide and inhibit its aggregation, as intact HDL does. This was assessed by SE-HPLC, SDS-PAGE, immunoblot analysis, ultrastructural electron microscopy and Congo Red staining for beta amyloid fibrils. Our data imply that A beta binding to lipids may play an important role in maintaining the peptide in solution and thus be particularly relevant to A beta normal and pathologic biochemistry and physiology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544446     DOI: 10.1016/s0009-8981(97)00207-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  29 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein.

Authors:  Judit Oláh; Orsolya Vincze; Dezsõ Virók; Dóra Simon; Zsolt Bozsó; Natália Tõkési; István Horváth; Emma Hlavanda; János Kovács; Anna Magyar; Mária Szũcs; Ferenc Orosz; Botond Penke; Judit Ovádi
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

3.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

4.  Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model.

Authors:  Yujie Cui; Mingwei Huang; Yingbo He; Shuyan Zhang; Yongzhang Luo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 5.  ATP-binding cassette transporter A1: from metabolism to neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Neurobiol Dis       Date:  2014-05-17       Impact factor: 5.996

6.  Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Authors:  Tina Bilousova; Mikhail Melnik; Emily Miyoshi; Bianca L Gonzalez; Wayne W Poon; Harry V Vinters; Carol A Miller; Maria M Corrada; Claudia Kawas; Asa Hatami; Ricardo Albay; Charles Glabe; Karen H Gylys
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

7.  Alzheimer's Abeta1-40 peptide modulates lipid synthesis in neuronal cultures and intact rat fetal brain under normoxic and oxidative stress conditions.

Authors:  N V Koudinova; A R Koudinov; E Yavin
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

8.  Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.

Authors:  Lesley Jones; Peter A Holmans; Marian L Hamshere; Denise Harold; Valentina Moskvina; Dobril Ivanov; Andrew Pocklington; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Jaspreet Singh Pahwa; Nicola Jones; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Heike Kölsch; Hendrik van den Bussche; Isabella Heuser; Oliver Peters; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panos Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Eckhard Rüther; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; John Hardy; Michael C O'Donovan; Michael J Owen; Julie Williams
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 9.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

10.  Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Authors:  Aynun N Begum; Fusheng Yang; Edmond Teng; Shuxin Hu; Mychica R Jones; Emily R Rosario; Walter Beech; Beverly Hudspeth; Oliver J Ubeda; Greg M Cole; Sally A Frautschy
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.